Breakingviews - Pandemic boosts Chinese biotech cred
HONG KONG(Reuters Breakingviews) - Chinaâ€™s biotechnology sector is having a moment in the spotlight thanks to the pandemic. Little-known firms like the $5.3 billion CanSino Biologics are among front runners developing vaccines and treatments for Covid-19. They look set to go global despite rising diplomatic tensions between Beijing and the world.
